PATIENT-CENTRIC SOLUTIONS FOR OBESITY

150+

Clinical studies completed in metabolic diseases

100+

Clinical trial sites strategically located worldwide  

24,800+

Study participants enrolled early phase in clinical trials

Specialized expertise to accelerate obesity drug development

Experience trusted by patients, sites, and study teams

Our services are initiated from deep scientific expertise in disease pathophysiology, drug classes, methodologies, patient engagement, and two decades of experience in clinical research, development, and regulatory strategies exclusively for metabolic diseases, including a wealth of experience with obesity targets and respective study designs.

Team Experience - photo
Study Start Up- photo

Accelerating study start-up

Our specialized study start-up team and Hub & Spokes™ platform is a game-changer, ensuring streamlined country and site selection, improved enrollment, and accelerated study launch – providing a dramatic and positive impact on the timelines and the conduct of the entire clinical study.

data-driven, patient-centric recruitment strategies

Our data-driven, proactive recruitment strategies ensure that our clinical trials are enrolling eligible patients at the most qualified sites and engaging with the study participants throughout the study and beyond to promote retention and a positive experience.

Recruitment Strategies - photo

Examine our metabolic compound and device experience

SMALL MOLECULES

Insulin secretagogues
Sulfonylureas, meglitinides, glucokinase activators, GPR40, GPR119, GPR44 agonists
Insulin sensitizers 
Biguanides, PPAR agonists, SARMs, SIRT1 activators, 11beta-HSD1 inhibitors
Incretin/glucagon pathway modulators
Dipeptidyl peptidase-4 inhibitors, glucagon-receptor antagonists
SGLT-2 Inhibitors
Other oral agents
Diacylglycerol acyltransferase and ACC inhibitors, thyroid hormone receptor beta (TRβ) agonists, farnesoid X receptor (FXR) agonists, peroxisome proliferator-activated receptor, niacin derivatives, CCR2 antagonists, ileal bile acid transport (IBAT) inhibitors, PDF4 inhibitors, de novo lipogenesis (DGAT, SCD1 & ACC) inhibitors, cannabinoid 1 receptor modulator

BIOLOGICS

Insulins
Ultra-rapid, rapid-, long- and ultra-long acting NCEs, biosimilar insulins, inhaled and oral insulins
Incretins mimetics
Incretins (GLP-1, GIP, GCGR), mono, dual and triple agonists, oxyntomodulin analogs
Other glucoregulatory peptides & proteins
Amylin analogues, peptide YY (3-36), fibroblast growth factors (FGF21), insulin-like growth factor 1
Immune-modulation & beta cell regeneration
Monoclonal antibodies, islet neogenesis associated protein (INGAP)  

OLIGONUCLEOTIDES 

miRNA-based therapeutics

DEVICES

Artificial pancreas
Continuous glucose monitoring systems
Alternative routes of peptide administration
mHealth applications

latest resources | obesity